
Smith & Nephew plc
SNN
Updated: 23/09/2026, 18:10:28
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
No summaries found.
- Share price
- $26.77
- Market cap
- $11.24B
- Exchange
- NYSE
- Currency
- USD
- CEO
- Deepak S. Nath
- Employees
- 18,362
- IPO date
- 16/11/1999
- Beta
- 0.6879999999999999
- Last dividend
- $0.00
- Day range
- $26.75 – $27.26
- 52-week range
- $26.75 – $37.51
- 1-day performance
- -2.67%
- 1-year performance
- 0.06%
- Current drawdown (1Y)
- -28.65%
- CIK
- 0000845982
- CUSIP
- 83175M205
- ISIN
- US83175M2052
- Created
- 07/12/2025, 14:18:41
- Last update
- 23/09/2026, 18:10:28
Track Smith & Nephew plc with an AI analyst
See which prediction-market events move SNN, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Smith & Nephew plc (SNN) Q1 2026 Sales/Trading Call Transcript
Seeking Alpha • STOCK • 06/05/2026, 11:02:35
UK's Smith+Nephew keeps annual outlook, plans share buyback as quarterly revenue rises
Reuters • STOCK • 06/05/2026, 04:21:56
SNN vs. BSX: Which Stock Is the Better Value Option?
Zacks Investment Research • STOCK • 05/05/2026, 14:41:15
SNN's CARTIHEAL Cartilage Implant Beats Standard Care in 5-Year Study
Zacks Investment Research • STOCK • 24/04/2026, 13:40:44
SNN Launches ALLEVYN COMPLETE CARE Dressing for Wound Management
Zacks Investment Research • STOCK • 11/03/2026, 14:15:14
Smith & Nephew plc (SNN) Surpasses Earnings and Revenue Estimates
Market Data • Market Data • 03/03/2026, 08:00:06
Smith & Nephew plc (SNN) Q4 2025 Earnings Call Transcript
Seeking Alpha • STOCK • 02/03/2026, 13:07:54
Smith & Nephew posts sharp rise in profit and cash flow
Proactive Investors • STOCK • 02/03/2026, 03:47:41
UK medical products maker Smith & Nephew's annual profit jumps 15.5%
Reuters • STOCK • 02/03/2026, 03:17:10
Smith+Nephew signs distribution agreement with SI-BONE
GlobeNewsWire • STOCK • 23/02/2026, 17:30:00